Trial Profile
A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients With Stable Ischemic Stroke
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Vandefitemcel (Primary)
- Indications Stroke
- Focus Adverse reactions
- Sponsors SanBio
- 31 May 2018 According to a SanBio Group media release, this trial was addressed at an event held by California Institute for Regenerative Medicine (CIRM) on May 31, 2018.
- 26 Jan 2018 Results assessing safety and clinical outcomes (two years) associated with surgical implantation of SB623 in patients with stable chronic ischemic stroke, presented at the International Stroke Conference 2018.
- 24 Jun 2016 According to SanBio media release, interim (preliminary) results presented of this trial are presented at the International Society of Stem Cell Research Meeting.